knee osteoarthritis
Conditions
Interventions
Experimental group:Extracorporeal shock wave therapy
Sponsors
The Third Medical Center of the Chinese People's Liberation Army General Hospital
Eligibility
Sex/Gender
All
Age
40 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Meet the KOA diagnostic criteria; 2. Aged 40-75 years; 3. Those who have not undergone systemic treatment recently and have not taken painkillers; 4. The subjects voluntarily participated in this study, signed the informed consent form, willing to cooperate with filling in relevant data, and accepting follow-up.
Exclusion criteria
Exclusion criteria: 1. X-ray imaging manifestations are Kellgren-Lawrence grade IV, with significantly narrowed joint space and subchondral bone sclerosis; 2. The knee joint has received arthroscopic surgery or open surgery in the past; 3. Patients with other rheumatic immune diseases, such as: rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, ankylosing spondylitis, etc.; 4. Patients with secondary knee OA, such as: acute and chronic knee infection, tumor, tuberculosis, blood, traumatic diseases; 5. Patients with severe deformity of the knee joint, knee varus >10 degree, knee valgus >20 degree and complete disappearance of the joint space are not suitable for conservative treatment; 6. Suffering from severe primary cardiovascular disease, lung disease, metabolic disease, endocrine disease and abnormal blood coagulation mechanism or other serious diseases that affect survival; 7. Received acetaminophen, cartilage nutrition drugs, joint cavity injection drugs and other related treatments in the past three months; 8. Those who cannot cooperate with MRI examination and have contraindications to MRI examination; 9. Those with contraindications to extracorporeal shock wave therapy; 10. Pregnant or lactating patients; 11. Suspect or do have a history of alcohol or drug abuse, or, according to the judgment of the investigator, have other diseases that reduce the possibility of enrollment or complicate enrollment, etc., which are likely to cause loss to follow-up; 12. Patients with serious adverse reactions and contraindications to the use of celecoxib capsules; 13. Other situations in which the researcher believes that the experiment cannot be successfully completed.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index; | — |
Secondary
| Measure | Time frame |
|---|---|
| Visual Analogue Scale;Gait analysis;MRI T2mapping value; | — |
Countries
China
Contacts
Public ContactXing Gengyan
The Third Medical Center of the Chinese People's Liberation Army General Hospital
Outcome results
None listed